Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has disclosed recent transactions involving the purchase of 1,300 American Depositary Receipts (ADRs) by its board members and executives. This ...

"We have seen an alarming rise in diabetes over the past three decades, which reflects the increase in obesity, compounded by the impacts of the marketing of unhealthy food, a lack of physical ...

(Reuters) - Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com (NASDAQ: AMZN) launched a rival service ...

Vanguard Health Care Fund ( Trades, Portfolio) expanded its portfolio by adding four new stocks in the third quarter of 2024.

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.

Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related ...

The company said around 80,000 users of the tracker have reported they were unable to access branded versions of the drugs, ...

De Grey Mining (ASX:DEG) has increased the Hemi discovery mineral resource estimate by 700,000 ounces to 264 million tonnes at 1.3 grams per tonne gold for 11.2 million ounces of contained gold.

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...